Metyrapone (Su-4885) 是一种有效且具有口服活性的11β-羟化酶 (11β-hydroxylase)抑制剂,可抑制醛固酮 (aldosterone)的产生,也是一种细胞自噬 (autophagy)激活剂。Metyrapone 能抑制内源性肾上腺皮质激素的合成,也会影响行为和情绪。此外,Metyrapone 可通过下调 mTOR 通路增加自噬过程的效率,也能与恶臭假单胞菌 (Pseudomonas putida) 细胞色素 P-450 (CYP450) 相互作用。Metyrapone 可用于研究库兴氏综合征 (Cushing's syndrome) 和抑郁症。
生物活性 | Metyrapone (Su-4885) is a potent and orally active11β-hydroxylaseinhibitor and anautophagyactivator, also inhibits the production ofaldosterone. Metyrapone inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone increases the efficiency of autophagic process via downregulation ofmTORpathway, and interacts withPseudomonas putidacytochrome P-450. Metyrapone can be used for researching Cushing's syndrome and depression[1][2][3][4][5]. |
IC50& Target | 11β-hydroxylase, Aldosterone, CYP450, Autophagy[1][4][5] |
体外研究 (In Vitro) | Metyrapone (100 μM; 2 h) hyperactivates autophagy in HepG2, and delays the activation of apoptosis at severe endoplasmic reticulum (ER) stress[5].
|
体内研究 (In Vivo) | Metyrapone (25 or 50 mg/kg; SC, single dosage) decreases the stress-induced increase in plasma corticosterone levels, significantly impairs acquisition performance at high dosage, and increases open arm activity at low dosage[1].
Animal Model: | Male Sprague-Dawley rats (n=179; 270-300g)[1] | Dosage: | 25 or 50 mg/kg (in a volume of 2.0 mL/kg) | Administration: | SC, single dosage | Result: | Dose-dependently decreased the stress-induced increase in plasma corticosterone levels in the water maze test; the high level dose significantly impaired acquisition performance in the water maze and decreased fear-induced immobility; the lower dose increased open arm activity. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(441.95 mM;Need ultrasonic) H2O : ≥ 38 mg/mL(167.94 mM) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 4.4195 mL | 22.0975 mL | 44.1950 mL | 5 mM | 0.8839 mL | 4.4195 mL | 8.8390 mL | 10 mM | 0.4419 mL | 2.2097 mL | 4.4195 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: PBS Solubility: 100 mg/mL (441.95 mM); Clear solution; Need ultrasonic 2. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (11.05 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (11.05 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (11.05 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (11.05 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 4. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (11.05 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (11.05 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|